Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Insomnia Market, by Distribution Channel
1.4.2 Europe Insomnia Market, by Therapy Type
1.4.3 Europe Insomnia Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Insomnia Market
Chapter 4. Europe Insomnia Market by Distribution Channel
4.1 Europe Hospital Market by Country
4.2 Europe Retail Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Insomnia Market by Therapy Type
5.1 Europe Pharmacological Market by Country
5.2 Europe Non-Pharmacological Market by Country
Chapter 6. Europe Insomnia Market by Country
6.1 Germany Insomnia Market
6.1.1 Germany Insomnia Market by Distribution Channel
6.1.2 Germany Insomnia Market by Therapy Type
6.2 UK Insomnia Market
6.2.1 UK Insomnia Market by Distribution Channel
6.2.2 UK Insomnia Market by Therapy Type
6.3 France Insomnia Market
6.3.1 France Insomnia Market by Distribution Channel
6.3.2 France Insomnia Market by Therapy Type
6.4 Russia Insomnia Market
6.4.1 Russia Insomnia Market by Distribution Channel
6.4.2 Russia Insomnia Market by Therapy Type
6.5 Spain Insomnia Market
6.5.1 Spain Insomnia Market by Distribution Channel
6.5.2 Spain Insomnia Market by Therapy Type
6.6 Italy Insomnia Market
6.6.1 Italy Insomnia Market by Distribution Channel
6.6.2 Italy Insomnia Market by Therapy Type
6.7 Rest of Europe Insomnia Market
6.7.1 Rest of Europe Insomnia Market by Distribution Channel
6.7.2 Rest of Europe Insomnia Market by Therapy Type
Chapter 7. Company Profiles
7.1 Eisai Co., Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Product Launches and Product Expansions:
7.1.5.2 Approvals and Trails:
7.2 Takeda Pharmaceutical Company Limited
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Approvals and Trails:
7.3 Vanda Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Research & Development Expenses
7.3.4 Recent strategies and developments:
7.3.4.1 Approval and Trails:
7.4 Cadila Healthcare Ltd. (Zydus Cadila)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Sanofi S.A.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Geographical Expansions:
7.6 Merck Group
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.8 Viatris, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Acquisition and Mergers:
7.9.2.2 Geographical Expansions:
7.10. Purdue Pharma L.P.
7.10.1 Company Overview
Unique Offerings 